For an asymptomatic patient with 24 supraventricular tachycardia episodes over 14 days (longest 59 seconds) who is already on a calcium‑channel blocker (diltiazem or verapamil), is monitoring alone sufficient or should the medication be continued and the patient be referred for an electrophysiology study and possible ablation?

Monitoring Alone Is Insufficient—Continue Calcium-Channel Blocker and Refer for EP Study

For an asymptomatic patient with 24 SVT episodes over 14 days (longest 59 seconds) already on a calcium-channel blocker, you should continue the medication and refer for electrophysiology study with consideration for catheter ablation. The frequency of episodes (averaging 1.7 episodes per day) despite being on suppressive therapy indicates inadequate control and warrants definitive management.

Why Monitoring Alone Is Not Appropriate

The clinical scenario has fundamentally changed from what might have justified monitoring alone:

• Frequent breakthrough episodes: 24 episodes in 14 days while already on calcium-channel blocker therapy demonstrates treatment failure 1
• Medication ineffectiveness: The patient is experiencing recurrent SVT despite being on first-line suppressive therapy (diltiazem or verapamil), which should prevent most episodes 2
• High episode burden: Even though asymptomatic, this frequency of arrhythmia episodes represents a significant burden that may impact quality of life and potentially lead to tachycardia-induced cardiomyopathy with prolonged exposure

Algorithmic Approach

Step 1: Continue Current Calcium-Channel Blocker

• Do not discontinue the diltiazem or verapamil—it may be providing partial rate control during episodes
• The medication is preventing hemodynamic instability even if not preventing episodes entirely 3

Step 2: Refer to Electrophysiology

Catheter ablation is now first-line therapy for recurrent, symptomatic paroxysmal SVT with success rates of 95% and recurrence rates less than 5% 1, 2. The key considerations:

• "Symptomatic" includes frequent episodes: While the patient reports being asymptomatic during episodes, the sheer frequency (24 episodes in 14 days) constitutes a symptomatic burden requiring intervention
• Medication failure: The patient has already failed first-line suppressive therapy, which shifts the risk-benefit calculation strongly toward ablation 2
• Low procedural risk: Inadvertent heart block occurs in less than 1% of patients 1

Step 3: EP Study Objectives

The electrophysiology study will:

• Definitively identify the SVT mechanism (likely AVNRT, AVRT, or focal AT)
• Assess for accessory pathways
• Proceed directly to ablation if appropriate substrate identified 2

Common Pitfalls to Avoid

Pitfall #1: Assuming "asymptomatic" means no treatment needed

• Frequent episodes (even if not causing symptoms) represent failed medical therapy and justify definitive treatment
• The patient may be underreporting symptoms or have adapted to frequent episodes

Pitfall #2: Escalating medical therapy instead of referring

• Adding additional antiarrhythmic medications (Class Ic or III agents) is less effective than ablation and carries proarrhythmic risk 4, 1
• Class Ia agents have modest effectiveness and significant adverse effects 1

Pitfall #3: Delaying referral

• Early referral to cardiology/EP is recommended for all patients with recurrent SVT 5, 2
• Prolonged exposure to frequent tachycardia episodes may lead to cardiac remodeling

Evidence Strength

The recommendation for catheter ablation in recurrent SVT is supported by:

• 2015 ACC/AHA/HRS Guidelines 3 establishing calcium-channel blockers as first-line acute and chronic therapy
• Multiple recent reviews 1, 5, 2 consistently recommending ablation as first-line for recurrent symptomatic SVT
• High-quality outcome data showing 95% success rates and <5% recurrence with ablation 1

The evidence clearly indicates that 24 episodes in 14 days while on suppressive therapy represents treatment failure requiring escalation to definitive therapy, not continued observation.